Please use this identifier to cite or link to this item: doi:10.22028/D291-39583
Title: Epileptic Status in a PEDiatric cohort (ESPED) requiring intensive care treatment: A multicenter, national, two-year prospective surveillance study
Author(s): Meyer, Sascha
Langer, Jaro
Poryo, Martin
Bay, Johannes Goaliath
Wagenpfeil, Stefan
Heinrich, Beate
Nunold, Holger
Strzelczyk, Adam
Ebrahimi-Fakhari, Daniel
Language: English
Title: Epilepsia open
Volume: 2023
Publisher/Platform: Wiley
Year of Publication: 2023
Free key words: anti-seizure medication
diagnosis
follow- up
intensive care treatment
management
pediatric
seizure
status epilepticus
surveillance
therapy
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Objective The aim of this study was to provide seizure etiology, semiology, underlying conditions, and out-of- and in-hospital diagnostics, treatment, and outcome data on children with out-of- or in-hospital-onset status epilepticus (SE) according to the International League Against Epilepsy definition that required admission to the pediatric intensive care unit (PICU) for ≥4 hours. Methods This prospective national surveillance study on SE in childhood and adolescence was conducted over 2 years (07/2019-06/2021). Results This study examined 481 SE episodes in 481 children with a median age of 43 months (1 month to 17 years 11 months), of which 46.2% were female and 50.7% had a previous seizure history. The most frequent acute SE cause was a prolonged, complicated febrile seizure (20.6%). The most common initial seizure types were generalized seizures (49.9%), focal seizures (18.0%), and unknown types (12.1%); 40.5% of patients suffered from refractory SE and 5.0% from super-refractory SE. The three most common medications administered by nonmedically trained individuals were diazepam, midazolam, and antipyretics. The three most frequent anti-seizure medications (ASMs) administered by the emergency physician were midazolam, diazepam, and propofol. The three most common ASMs used in the clinical setting were midazolam, levetiracetam, and phenobarbital. New ASMs administered included lacosamide, brivaracetam, perampanel, stiripentol, and eslicarbazepine. Status epilepticus terminated in 16.0% in the preclinical setting, 19.1% in the emergency department, and 58.0% in the PICU; the outcome was unknown for 6.9%. The median PICU stay length was 2 (1–121) days. The median modified Rankin scale was 1 (0–5) on admission and 2 (0–6) at discharge. New neurological deficits after SE were observed in 6.2%. The mortality rate was 3.5%. Significance This study provides current real-world out-of- and in-hospital data on pediatric SE requiring PICU admission. New ASMs are more frequently used in this population. This knowledge may help generate a more standardized approach.
DOI of the first publication: 10.1002/epi4.12707
Link to this record: urn:nbn:de:bsz:291--ds-395836
hdl:20.500.11880/35674
http://dx.doi.org/10.22028/D291-39583
ISSN: 2470-9239
Date of registration: 18-Apr-2023
Third-party funds sponsorship: Dr Wolf Epilepsy, Grant/Award Number: N/A
Faculty: M - Medizinische Fakultät
Department: M - Medizinische Biometrie, Epidemiologie und medizinische Informatik
Professorship: M - Prof. Dr. Stefan Wagenpfeil
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



This item is licensed under a Creative Commons License Creative Commons